GLP-one RAs for CVD: Are Cardiologists Ready?

GLP-one RAs for CVD: Are Cardiologists Ready?

The favourable effects from the Select demo for the glucagon-like peptide-1 receptor agonists (GLP-1 RAs) had been hailed as ushering in a “new era for sufferers with being overweight.” In the demo of chubby and obese individuals with cardiovascular ailment (CVD), but no diabetes, semaglutide confirmed meaningful reductions in cardiovascular demise…
Read More

You May Also Like